
Jeffrey A Johnson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1576387/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mapping the Edmonton Symptom Assessment System-Revised: Renal to the EQ-5D-5L in patients with chronic kidney disease. Quality of Life Research, 2022, 31, 567-577.	1.5	3
2	Small differences in EQ-5D-5L health utility scores were interpreted differently between and within respondents. Journal of Clinical Epidemiology, 2022, 142, 133-143.	2.4	2
3	Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology. Nature Communications, 2022, 13, 135.	5.8	97
4	The impact of COVID-19 pandemic on health-related quality of life of adults visiting emergency departments and primary care settings in Alberta. Canadian Journal of Public Health, 2022, 113, 96-106.	1.1	6
5	Enhancing Diabetes Surveillance Across Alberta by Adding Laboratory and Pharmacy Data to the National Diabetes Surveillance System Methods. Canadian Journal of Diabetes, 2022, 46, 375-380.	0.4	6
6	Comparative performance of the EuroQol EQ-5D-5L and the CDC healthy days measures in assessing population health. Journal of Patient-Reported Outcomes, 2022, 6, .	0.9	0
7	Health-related quality-of-life and health-utility reporting in critical care. World Journal of Critical Care Medicine, 2022, 11, 236-245.	0.8	4
8	Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ, The, 2021, 372, m4743.	3.0	186
9	The performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings. Health and Quality of Life Outcomes, 2021, 19, 96.	1.0	16
10	Effect of a pharmacy comprehensive chronic diseases care plan on use of lipid-lowering drugs among patients with hypertension. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 426-434.	0.5	0
11	Adopting and implementing an innovative model to organize diabetes care within First Nations communities: A qualitative assessment. BMC Health Services Research, 2021, 21, 415.	0.9	1
12	The predictive ability of EQ-5D-3L compared to the LACE index and its association with 30-day post-hospitalization outcomes. Quality of Life Research, 2021, 30, 2583-2590.	1.5	2
13	Modifying the quality-adjusted life year calculation to account for meaningful change in health-related quality of life: insights from a pragmatic clinical trial. European Journal of Health Economics, 2021, 22, 1441-1451.	1.4	0
14	Exploring the impact of pharmacist comprehensive annual care plans on perceived quality of chronic illness care by patients in Alberta, Canada. Canadian Pharmacists Journal, 2021, 154, 331-341.	0.4	0
15	Economic Evaluation of Sucrose Octasulfate Dressing for the Treatment of Diabetic Foot Ulcers for Type 2 Diabetes Patients. Canadian Journal of Diabetes, 2021, , .	0.4	3
16	Measuring value in healthcare from a patients' perspective. Journal of Patient-Reported Outcomes, 2021, 5, 88.	0.9	6
17	Selection of patient-reported outcome measures (PROMs) for use in health systems. Journal of Patient-Reported Outcomes, 2021, 5, 99.	0.9	25
18	Patient-reported outcome measures in the care of in-centre hemodialysis patients. Journal of Patient-Reported Outcomes, 2021, 5, 93.	0.9	9

#	Article	IF	CITATIONS
19	A multi-level approach for the use of routinely collected patient-reported outcome measures (PROMs) data in healthcare systems. Journal of Patient-Reported Outcomes, 2021, 5, 98.	0.9	19
20	Burden of mental health symptoms and perceptions of their management in in-centre hemodialysis care: a mixed methods study. Journal of Patient-Reported Outcomes, 2021, 5, 111.	0.9	7
21	Effect of a pharmacy comprehensive chronic diseases care plan on use of lipid-lowering drugs among patients with hypertension. Journal of Managed Care & Specialty Pharmacy, 2021, 27, 426-434.	0.5	Ο
22	Factors associated with pneumococcal vaccination in 2040 people with type 2 diabetes: A cross-sectional study. Diabetes and Metabolism, 2020, 46, 137-143.	1.4	5
23	A Longitudinal Study on the Association Between Diabetic Foot Disease and Health-Related Quality of Life in Adults With Type 2 Diabetes. Canadian Journal of Diabetes, 2020, 44, 280-286.e1.	0.4	12
24	Patients' Experiences of Nurse Case-Managed Osteoporosis Care: A Qualitative Study. Journal of Patient Experience, 2020, 7, 251-257.	0.4	3
25	Healthy Eating and Active Living for Diabetes-Glycemic Index (HEALD-GI): A Pragmatic Randomized Controlled Trial. Current Developments in Nutrition, 2020, 4, nzaa059_006.	0.1	1
26	Feasibility of identifying and describing the burden of early-onset metabolic syndrome in primary care electronic medical record data: a cross-sectional analysis. CMAJ Open, 2020, 8, E779-E787.	1.1	7
27	3125 steps to perfect health: a nonparametric approach to developing the EQ-5D-5L value set. Quality of Life Research, 2020, 29, 3109-3118.	1.5	0
28	A cluster randomized controlled trial for the Evaluation of routinely Measured PATient reported outcomes in HemodialYsis care (EMPATHY): a study protocol. BMC Health Services Research, 2020, 20, 731.	0.9	23
29	Working towards a better understanding of type 2 diabetes care organization with First Nations communities: a qualitative assessment. Archives of Public Health, 2020, 78, 7.	1.0	2
30	Angiogenin activates the astrocytic Nrf2/antioxidant-response element pathway and thereby protects murine neurons from oxidative stress. Journal of Biological Chemistry, 2019, 294, 15095-15103.	1.6	23
31	Validation of drug prescription records for senior patients in Alberta's Tomorrow Project: Assessing agreement between two populationâ€level administrative pharmaceutical databases in Alberta, Canada. Pharmacoepidemiology and Drug Safety, 2019, 28, 1417-1421.	0.9	10
32	Women's experience with peer counselling and social support during a lifestyle intervention among women with a previous gestational diabetes pregnancy. Health Psychology and Behavioral Medicine, 2019, 7, 147-159.	0.8	8
33	Optimal threshold of adherence to lipid lowering drugs in predicting acute coronary syndrome, stroke, or mortality: A cohort study. PLoS ONE, 2019, 14, e0223062.	1.1	6
34	Changing provider behaviour to increase nurse visits for obesity in family practice: the 5As Team randomized controlled trial. CMAJ Open, 2019, 7, E371-E378.	1.1	5
35	Responsiveness of the EQ-5D-3L and EQ-5D-5L in patients following total hip or knee replacement. Quality of Life Research, 2019, 28, 2409-2417.	1.5	25
36	Discriminative validity of the EQ-5D-5 L and SF-12 in older adults with arthritis. Health and Quality of Life Outcomes, 2019, 17, 68.	1.0	14

#	Article	IF	CITATIONS
37	Systematic review of community pharmacy–based and pharmacist-led foot care interventions for adults with type 2 diabetes. Canadian Pharmacists Journal, 2019, 152, 109-116.	0.4	11
38	An individualized patient-reported outcome measure (PROM) based patient decision aid and surgeon report for patients considering total knee arthroplasty: protocol for a pragmatic randomized controlled trial. BMC Musculoskeletal Disorders, 2019, 20, 89.	0.8	31
39	Cost-Effectiveness of Osteoporosis Interventions to Improve Quality of Care After Upper Extremity Fracture: Results From a Randomized Trial (C-STOP Trial). Journal of Bone and Mineral Research, 2019, 34, 1220-1228.	3.1	13
40	Anthropometric changes and risk of diabetes: are there sex differences? A longitudinal study of Alberta's Tomorrow Project. BMJ Open, 2019, 9, e023829.	0.8	8
41	The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA. Clinical Orthopaedics and Related Research, 2019, 477, 1632-1644.	0.7	20
42	Individualized health-related quality of life instrument Measure Yourself Medical Outcome Profile (MYMOP) and its adaptations: a critical appraisal. Quality of Life Research, 2019, 28, 879-893.	1.5	11
43	Association of Depressive Symptoms and Diabetes Distress With Severe Hypoglycemia in Adults With Type 2 Diabetes. Canadian Journal of Diabetes, 2019, 43, 316-321.	0.4	8
44	Adherence to osteoporosis therapy after an upper extremity fracture: a pre-specified substudy of the C-STOP randomized controlled trial. Osteoporosis International, 2019, 30, 127-134.	1.3	21
45	Healthy Eating and Active Living for Diabetes-Glycemic Index (HEALD-Gl): Protocol for a Pragmatic Randomized Controlled Trial. JMIR Research Protocols, 2019, 8, e11707.	0.5	0
46	Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health. Quality of Life Research, 2018, 27, 1625-1633.	1.5	17
47	Health-related quality of life and its determinants in paediatric arterial ischaemic stroke survivors. Archives of Disease in Childhood, 2018, 103, 930-936.	1.0	18
48	Genome-wide association study identifies pharmacogenomic loci linked with specific antihypertensive drug treatment and new-onset diabetes. Pharmacogenomics Journal, 2018, 18, 106-112.	0.9	7
49	Changes in glucose-lowering drug use before and after cancer diagnosis in patients with diabetes. Diabetes and Metabolism, 2018, 44, 22-29.	1.4	5
50	Development of Perinatal Mental Illness in Women With Gestational Diabetes Mellitus: A Population-Based Cohort Study. Canadian Journal of Diabetes, 2018, 42, 350-355.e1.	0.4	25
51	Risk of prostate cancer across different racial/ethnic groups in men with diabetes: a retrospective cohort study. Diabetic Medicine, 2018, 35, 107-111.	1.2	8
52	Systemic use of antibiotics and risk of diabetes in adults: <scp>A</scp> nested case ontrol study of <scp>Alberta's Tomorrow Project</scp> . Diabetes, Obesity and Metabolism, 2018, 20, 849-857.	2.2	8
53	Changes in body mass index and incidence of diabetes: A longitudinal study of Alberta's Tomorrow Project Cohort. Preventive Medicine, 2018, 106, 157-163.	1.6	14
54	History of mood or anxiety disorders and risk of gestational diabetes mellitus in a populationâ€based cohort. Diabetic Medicine, 2018, 35, 147-151.	1.2	14

#	Article	IF	CITATIONS
55	Screening for Anxiety and Depressive Symptoms in Type 2 Diabetes Using Patient-Reported Outcome Measures: Comparative Performance of the EQ-5D-5L and SF-12v2. MDM Policy and Practice, 2018, 3, 238146831879936.	0.5	6
56	Population attributable fractions for Type 2 diabetes: an examination of multiple risk factors including symptoms of depression and anxiety. Diabetology and Metabolic Syndrome, 2018, 10, 84.	1.2	9
57	Minimally Important Difference of the EQ-5D-5L Index Score in Adults with Type 2 Diabetes. Value in Health, 2018, 21, 1090-1097.	0.1	54
58	Comparing Strategies Targeting Osteoporosis to Prevent Fractures After an Upper Extremity Fracture (C-STOP Trial): A Randomized Controlled Trial. Journal of Bone and Mineral Research, 2018, 33, 2114-2121.	3.1	23
59	The association of self-efficacy and hospitalization rates in people with type-2 diabetes: A prospective cohort study. Diabetes Research and Clinical Practice, 2018, 143, 113-119.	1.1	5
60	Metformin, Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis. BMC Cancer, 2018, 18, 65.	1.1	24
61	The relationship of neighbourhood-level material and social deprivation with health-related quality of Life Research, 2018, 27, 3265-3274.	1.5	15
62	Sex differences in obesity related cancer incidence in relation to type 2 diabetes diagnosis (ZODIAC-49). PLoS ONE, 2018, 13, e0190870.	1.1	12
63	Validation of administrative data case definitions for gestational diabetes mellitus. Diabetic Medicine, 2017, 34, 51-55.	1.2	27
64	Handling Regional Variation in Health State Preferences within a Country. Medical Decision Making, 2017, 37, 252-261.	1.2	2
65	Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores. Value in Health, 2017, 20, 644-650.	0.1	170
66	Metformin and the risk of prostate cancer across racial/ethnic groups: a population-based cohort study. Prostate Cancer and Prostatic Diseases, 2017, 20, 122-126.	2.0	17
67	Type 2 Diabetes and Comorbid Symptoms of Depression and Anxiety: Longitudinal Associations With Mortality Risk. Diabetes Care, 2017, 40, 352-358.	4.3	102
68	Physical Activity and Health-Related Quality of Life in Adults With Type 2 Diabetes: Results From a Prospective Cohort Study. Journal of Physical Activity and Health, 2017, 14, 368-374.	1.0	14
69	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogeneticsâ€Guided Warfarin Dosing: 2017 Update. Clinical Pharmacology and Therapeutics, 2017, 102, 397-404.	2.3	479
70	Health literacy and logical inconsistencies in valuations of hypothetical health states: results from the Canadian EQ-5D-5L valuation study. Quality of Life Research, 2017, 26, 1483-1492.	1.5	5
71	Differences in Short―and Longâ€Term Mortality Associated With BMI Following Coronary Revascularization. Journal of the American Heart Association, 2017, 6, .	1.6	21
72	Postpartum Diabetes Testing Rates after Gestational Diabetes Mellitus in Canadian Women: A Population-Based Study. Canadian Journal of Diabetes, 2017, 41, 613-620.	0.4	18

#	Article	IF	CITATIONS
73	Population-Level Outcomes with a 2-Step Approach for Gestational Diabetes Screening and Diagnosis. Canadian Journal of Diabetes, 2017, 41, 596-602.	0.4	11
74	Patterns of glucoseâ€lowering therapies and neonatal outcomes in the treatment of gestational diabetes in Canada, 2009–2014. Diabetic Medicine, 2017, 34, 1296-1302.	1.2	12
75	Impact of the 5As Team study on clinical practice in primary care obesity management: a qualitative study. CMAJ Open, 2017, 5, E322-E329.	1.1	17
76	Comparative performance of the EQ-5D-5L and SF-6D index scores in adults with type 2 diabetes. Quality of Life Research, 2017, 26, 2057-2066.	1.5	33
77	Measuring socioeconomic inequalities in eye care services among patients with diabetes in Alberta, Canada, 1995–2009. Diabetes Research and Clinical Practice, 2017, 127, 205-211.	1.1	11
78	Time-Varying Risk for Breast Cancer Following Initiation of Glucose-Lowering Therapy in Women with Type 2 Diabetes: Exploring Detection Bias. Canadian Journal of Diabetes, 2017, 41, 204-210.	0.4	3
79	Body Mass Index Is Associated With Differential Rates of Coronary Revascularization After Cardiac Catheterization. Canadian Journal of Cardiology, 2017, 33, 822-829.	0.8	3
80	Healthy eating and active living after gestational diabetes mellitus (HEALD-GDM): Rationale, design, and proposed evaluation of a randomized controlled trial. Contemporary Clinical Trials, 2017, 61, 23-28.	0.8	3
81	Cohort Profile: Alberta's Tomorrow Project. International Journal of Epidemiology, 2017, 46, 1097-1098l.	0.9	44
82	Symptoms of anxiety and depression in type 2 diabetes: Associations with clinical diabetes measures and self-management outcomes in the Norwegian HUNT study. Psychoneuroendocrinology, 2017, 84, 116-123.	1.3	35
83	The 5As team patient study: patient perspectives on the role of primary care in obesity management. BMC Family Practice, 2017, 18, 19.	2.9	29
84	Within-class differences in cancer risk for sulfonylurea treatments in patients with type 2 diabetes (ZODIAC-55) – a study protocol. BMC Cancer, 2017, 17, 444.	1.1	4
85	Addressing the gaps in diabetes care in first nations communities with the reorganizing the approach to diabetes through the application of registries (RADAR): the project protocol. BMC Health Services Research, 2017, 17, 117.	0.9	7
86	Validation of administrative and clinical case definitions for gestational diabetes mellitus against laboratory results. Diabetic Medicine, 2017, 34, 781-785.	1.2	14
87	Prevalence of gestational diabetes among Chinese and South Asians: A Canadian population-based analysis. Journal of Diabetes and Its Complications, 2017, 31, 529-536.	1.2	23
88	Walking and type 2 diabetes risk using CANRISK scores among older adults. Applied Physiology, Nutrition and Metabolism, 2017, 42, 33-38.	0.9	9
89	Association between Physical Activity and Health-Related Quality of Life in Adults with Type 2 Diabetes. Canadian Journal of Diabetes, 2017, 41, 58-63.	0.4	53
90	Understanding fragility fracture patients' decision-making process regarding bisphosphonate treatment. Osteoporosis International, 2017, 28, 219-229.	1.3	21

#	Article	IF	CITATIONS
91	Geographic Clustering of Acute Complications and Sociodemographic Factors in Adults with Type 1 Diabetes. Canadian Journal of Diabetes, 2017, 41, 132-137.	0.4	8
92	Engaging Patients and Clinicians in Establishing Research Priorities for Gestational Diabetes Mellitus. Canadian Journal of Diabetes, 2017, 41, 156-163.	0.4	28
93	Examining Diet-Related Care Practices Among Adults with Type 2 Diabetes: A Focus on Glycemic Index Choices. Canadian Journal of Dietetic Practice and Research, 2017, 78, 26-31.	0.5	2
94	Correlates of accelerometer-assessed physical activity and sedentary time among adults with type 2 diabetes. Canadian Journal of Public Health, 2017, 108, 355-361.	1.1	9
95	Objectively measured sleep and health-related quality of life in older adults with type 2 diabetes: a cross-sectional study from the Alberta's Caring for Diabetes Study. Sleep Health, 2017, 3, 102-106.	1.3	9
96	Cost-effectiveness of a school-based health promotion program in Canada: A life-course modeling approach. PLoS ONE, 2017, 12, e0177848.	1.1	23
97	Development and validation of an index score to adjust for healthy user bias in observational studies. Journal of Population Therapeutics and Clinical Pharmacology, 2017, 24, e79-e89.	1.9	3
98	Health Behaviours and Awareness of Canada's Food Guide: A Population-based Study. Canadian Journal of Dietetic Practice and Research, 2016, 77, 66-71.	0.5	5
99	A qualitative study examining healthcare managers and providers' perspectives on participating in primary care implementation research. BMC Health Services Research, 2016, 16, 316.	0.9	4
100	A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Medical Care, 2016, 54, 98-105.	1.1	290
101	Determinants of time trade-off valuations for EQ-5D-5L health states: data from the Canadian EQ-5D-5L valuation study. Quality of Life Research, 2016, 25, 1679-1685.	1.5	27
102	The relationship of diabetes-related distress and depressive symptoms with physical activity and dietary behaviors in adults with type 2 diabetes: A cross-sectional study. Journal of Diabetes and Its Complications, 2016, 30, 967-970.	1.2	17
103	How different are composite and traditional TTO valuations of severe EQ-5D-5L states?. Quality of Life Research, 2016, 25, 2101-2108.	1.5	7
104	Current depressive symptoms but not history of depression predict hospital readmission or death after discharge from medical wards: a multisite prospective cohort study. General Hospital Psychiatry, 2016, 39, 80-85.	1.2	16
105	Safety of Concomitant Metformin and Proton Pump Inhibitor Use: A Population Retrospective Cohort Study. Clinical Therapeutics, 2016, 38, 1392-1400.	1.1	6
106	Income-related inequalities in visual impairment and eye screening services in patients with type 2 diabetes. Journal of Public Health, 2016, 38, e571-e579.	1.0	7
107	Check the score: Field validation of Street Smart Walk Score in Alberta, Canada. Preventive Medicine Reports, 2016, 4, 532-539.	0.8	43
108	Melatonin Pathway and Atenololâ€Related Glucose Dysregulation: Is There a Correlation?. Clinical and Translational Science, 2016, 9, 114-122.	1.5	12

#	Article	IF	CITATIONS
109	Genetic and Nongenetic Factors Affecting Clopidogrel Response in the Egyptian Population. Clinical and Translational Science, 2016, 9, 23-28.	1.5	32
110	The temporal relationship between diabetes and cancer: A populationâ€based study. Cancer, 2016, 122, 2731-2738.	2.0	29
111	A22â€Genetic tools to validate and measure NRF2 in HD. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A6.4-A7.	0.9	4
112	Cost-Effectiveness Evaluation of Collaborative Care for Diabetes and Depression in Primary Care. American Journal of Preventive Medicine, 2016, 51, e13-e20.	1.6	18
113	Severe Obesity Is Associated With Increased Risk of Early Complications and Extended Length of Stay Following Coronary Artery Bypass Grafting Surgery. Journal of the American Heart Association, 2016, 5, .	1.6	36
114	Dietary Patterns in Adults with Type 2 Diabetes Predict Cardiometabolic Risk Factors. Canadian Journal of Diabetes, 2016, 40, 296-303.	0.4	4
115	Temporal variation of diabetic ketoacidosis and hypoglycemia in adults with type 1 diabetes: A nationwide cohort study. Journal of Diabetes, 2016, 8, 552-558.	0.8	11
116	Outcomes of singleton and twin pregnancies complicated by preâ€existing diabetes and gestational diabetes: A populationâ€based study in <scp>A</scp> lberta, <scp>C</scp> anada, 2005–11. Journal of Diabetes, 2016, 8, 45-55.	0.8	69
117	Testing social-cognitive mediators for objective estimates of physical activity from the Healthy Eating and Active Living for Diabetes in Primary Care Networks (HEALD-PCN) study. Psychology, Health and Medicine, 2016, 21, 945-953.	1.3	2
118	Health literacy and health-related quality of life in adults with type 2 diabetes: a longitudinal study. Quality of Life Research, 2016, 25, 1487-1494.	1.5	32
119	How dead is dead? Qualitative findings from participants of combined traditional and lead-time time trade-off valuations. Quality of Life Research, 2016, 25, 35-43.	1.5	12
120	Prevalence and Timing of Screening and Diagnostic Testing for Gestational Diabetes Mellitus: A Population-Based Study in Alberta, Canada. Diabetes Care, 2016, 39, 55-60.	4.3	33
121	How much will we pay to increase steps per day? Examining the cost-effectiveness of a pedometer-based lifestyle program in primary care. Preventive Medicine Reports, 2015, 2, 645-650.	0.8	7
122	Increase in Daily Steps After an Exercise Specialist Led Lifestyle Intervention for Adults With Type 2 Diabetes in Primary Care: A Controlled Implementation Trial. Journal of Physical Activity and Health, 2015, 12, 1492-1499.	1.0	17
123	Pharmacists on primary care teams: Effect on antihypertensive medication management in patients with type 2 diabetes. Journal of the American Pharmacists Association: JAPhA, 2015, 55, 265-268.	0.7	8
124	Alternation as a form of allocation for quality improvement studies in primary healthcare settings: the on-off study design. Trials, 2015, 16, 375.	0.7	12
125	Costâ€effectiveness analysis of adding pharmacists to primary care teams to reduce cardiovascular risk in patients with TypeÂ2 diabetes: results from a randomized controlled trial. Diabetic Medicine, 2015, 32, 899-906.	1.2	38
126	Age at stroke onset influences the clinical outcome and healthâ€related quality of life in pediatric ischemic stroke survivors. Developmental Medicine and Child Neurology, 2015, 57, 1027-1034.	1.1	27

#	Article	IF	CITATIONS
127	Rates and Correlates of Relapse Following ED Discharge for Acute Asthma. Chest, 2015, 147, 140-149.	0.4	17
128	Relationship Between Duration of Type 2 Diabetes and Self-Reported Participation in Diabetes Education in Korea. Asia-Pacific Journal of Public Health, 2015, 27, NP311-NP321.	0.4	3
129	Impact of gestational diabetes mellitus and high maternal weight on the development of diabetes, hypertension and cardiovascular disease: a populationâ€level analysis. Diabetic Medicine, 2015, 32, 164-173.	1.2	87
130	Limited Impact of Drug Exposure Misclassification From Non-Benefit Thiazolidinedione Drug Use on Mortality and Hospitalizations From Saskatchewan, Canada: A Cohort Study. Clinical Therapeutics, 2015, 37, 629-642.	1.1	0
131	A Cyclic Peptide Mimic of the β-Amyloid Binding Domain on Transthyretin. ACS Chemical Neuroscience, 2015, 6, 778-789.	1.7	23
132	Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes. Diabetologia, 2015, 58, 951-960.	2.9	36
133	Socioeconomic factors associated with visual impairment and ophthalmic care utilization in patients with type II diabetes. Canadian Journal of Ophthalmology, 2015, 50, 119-126.	0.4	29
134	Characteristics and health behaviors of diabetic patients receiving influenza vaccination. Vaccine, 2015, 33, 3549-3555.	1.7	14
135	Long-Term Association Between Frailty and Health-Related Quality of Life Among Survivors of Critical Illness. Critical Care Medicine, 2015, 43, 973-982.	0.4	189
136	Associations Between Health Literacy and Health Outcomes in a Predominantly Low-Income African American Population with Type 2 Diabetes. Journal of Health Communication, 2015, 20, 581-588.	1.2	28
137	Association of Inadequate Health Literacy with Health Outcomes in Patients with Type 2 Diabetes and Depression: Secondary Analysis of a Controlled Trial. Canadian Journal of Diabetes, 2015, 39, 259-265.	0.4	33
138	Impact of cancer on use of glucose-lowering drug treatment in individuals with diabetes: potential mechanisms. Reply to Pouwer F [letter]. Diabetologia, 2015, 58, 1380-1381.	2.9	2
139	Challenges in Identifying Patients with Type 2 Diabetes for Quality-Improvement Interventions in Primary Care Settings and the Importance of Valid Disease Registries. Canadian Journal of Diabetes, 2015, 39, S77-S82.	0.4	9
140	Prompted awareness and use of <i>Eating Well with Canada's Food Guide</i> : a populationâ€based study. Journal of Human Nutrition and Dietetics, 2015, 28, 64-71.	1.3	12
141	Impact of Organizational Stability on Adoption of Quality-Improvement Interventions for Diabetes in Primary Care Settings. Canadian Journal of Diabetes, 2015, 39, S100-S112.	0.4	6
142	Contextualizing the Effectiveness of a Collaborative Care Model forÂPrimary Care Patients with Diabetes and Depression (Teamcare): A Qualitative Assessment Using RE-AIM. Canadian Journal of Diabetes, 2015, 39, S83-S91.	0.4	30
143	Nrf2—a therapeutic target for the treatment of neurodegenerative diseases. Free Radical Biology and Medicine, 2015, 88, 253-267.	1.3	262
144	Contextualizing the Proven Effectiveness of a Lifestyle Intervention for Type 2 Diabetes in Primary Care: A Qualitative Assessment Based on the RE-AIM Framework. Canadian Journal of Diabetes, 2015, 39, S92-S99.	0.4	9

#	Article	IF	CITATIONS
145	The Alberta's Caring for Diabetes (ABCD) Study: Rationale, Design and Baseline Characteristics of a Prospective Cohort of Adults with Type 2 Diabetes. Canadian Journal of Diabetes, 2015, 39, S113-S119.	0.4	26
146	Diabetic Foot Disease, Self-Care and Clinical Monitoring in Adults with Type 2 Diabetes: The Alberta's Caring for Diabetes (ABCD) Cohort Study. Canadian Journal of Diabetes, 2015, 39, S120-S126.	0.4	39
147	The safety of sulfonylurea therapy in type 2 diabetes: have we reached the practical limits of our evidence base?. Diabetologia, 2015, 58, 1-3.	2.9	29
148	Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia, 2015, 58, 493-504.	2.9	140
149	Increased Alzheimer's disease–like pathology in the APP/ PS1î"E9 mouse model lacking Nrf2 through modulation of autophagy. Neurobiology of Aging, 2015, 36, 664-679.	1.5	147
150	Comment on Bordeleau et al. The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia. Diabetes Care 2014;37:1360–1366. Diabetes Care, 2014, 37, e221-e222.	4.3	4
151	Collaborative Care Versus Screening and Follow-up for Patients With Diabetes and Depressive Symptoms: Results of a Primary Care–Based Comparative Effectiveness Trial. Diabetes Care, 2014, 37, 3220-3226.	4.3	63
152	Predictors of healthâ€related quality of life in 500 severely obese patients. Obesity, 2014, 22, 1367-1372.	1.5	26
153	Sex-based disparities in cardioprotective medication use in adults with diabetes. Diabetology and Metabolic Syndrome, 2014, 6, 117.	1.2	12
154	Weight loss required by the severely obese to achieve clinically important differences in health-related quality of life: two-year prospective cohort study. BMC Medicine, 2014, 12, 175.	2.3	96
155	Health Literacy and Nurses' Communication With Type 2 Diabetes Patients in Primary Care Settings. Nursing Research, 2014, 63, 408-417.	0.8	38
156	Implementation and evaluation of the 5As framework of obesity management in primary care: design of the 5As Team (5AsT) randomized control trial. Implementation Science, 2014, 9, 78.	2.5	34
157	Profile of adults with type 2 diabetes and uptake of clinical care best practices: Results from the 2011 Survey on Living with Chronic Diseases in Canada $\hat{a} \in$ Diabetes component. Diabetes Research and Clinical Practice, 2014, 103, 11-19.	1.1	10
158	Association Between Diabetic Ketoacidosis Hospitalizations and Driving Distance to Outpatient Diabetes Centres in Adults with TypeÂ1 Diabetes Mellitus. Canadian Journal of Diabetes, 2014, 38, 451-455.	0.4	10
159	Assessment of children's own health status using visual analogue scale and descriptive system of the EQ-5D-Y: linkage between two systems. Quality of Life Research, 2014, 23, 393-402.	1.5	21
160	Working-age adults with diabetes experience greater susceptibility to seasonal influenza: a population-based cohort study. Diabetologia, 2014, 57, 690-698.	2.9	29
161	The effect of weight loss on healthâ€related quality of life: systematic review and metaâ€analysis of randomized trials. Obesity Reviews, 2014, 15, 169-182.	3.1	150
162	Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study. Diabetes, Obesity and Metabolism, 2014, 16, 22-29.	2.2	18

#	Article	IF	CITATIONS
163	Oxidative damage and the Nrf2-ARE pathway in neurodegenerative diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 1208-1218.	1.8	231
164	Effect of Vitamin D ₃ Supplementation on Improving Glucose Homeostasis and Preventing Diabetes: A Systematic Review and Meta-Analysis. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3551-3560.	1.8	221
165	Critical impact of patient knowledge and bone density testing on starting osteoporosis treatment after fragility fracture: secondary analyses from two controlled trials. Osteoporosis International, 2014, 25, 2173-2179.	1.3	20
166	Comparing the EQ-5D 3L and 5L: measurement properties and association with chronic conditions and multimorbidity in the general population. Health and Quality of Life Outcomes, 2014, 12, 74.	1.0	114
167	Measurement properties and comparative performance of health literacy screening questions in a predominantly low income African American population with diabetes. Patient Education and Counseling, 2014, 97, 88-95.	1.0	13
168	A primary care based healthy-eating and active living education session for weight reduction in the pre-diabetic population. Primary Care Diabetes, 2014, 8, 301-307.	0.9	4
169	Changes in Thiazolidinedione Use and Outcomes Following Removal of a Prior-authorization Policy. Medical Care, 2014, 52, 47-55.	1.1	3
170	Social support, selfâ€efficacy and motivation: a qualitative study of the journey through <scp>HEALD</scp> (Healthy Eating and Active Living for Diabetes). Practical Diabetes, 2014, 31, 370-374.	0.1	5
171	Life Course Impact of School-Based Promotion of Healthy Eating and Active Living to Prevent Childhood Obesity. PLoS ONE, 2014, 9, e102242.	1.1	18
172	Mental health and the relationship between health promotion counseling and health outcomes in chronic conditions: cross-sectional population-based study. Canadian Family Physician, 2014, 60, e113-20.	0.1	2
173	Health-related quality of life and healthcare utilization in multimorbidity: results of a cross-sectional survey. Quality of Life Research, 2013, 22, 791-799.	1.5	144
174	Determinants of lifestyle behavior in type 2 diabetes: results of the 2011 cross-sectional survey on living with chronic diseases in Canada. BMC Public Health, 2013, 13, 451.	1.2	22
175	Health Literacy and Health Outcomes in Diabetes: A Systematic Review. Journal of General Internal Medicine, 2013, 28, 444-452.	1.3	283
176	Concordance Between Self-Report and a Survey-Based Algorithm for Classification of Type 1 and Type 2 Diabetes Using the 2011 Population-Based Survey on Living With Chronic Diseases in Canada (SLCDC)-Diabetes Component. Canadian Journal of Diabetes, 2013, 37, 249-253.	0.4	13
177	Multimorbidity prevalence in the general population: the role of obesity in chronic disease clustering. BMC Public Health, 2013, 13, 1161.	1.2	101
178	Health Behaviors for Hypertension Management in People With and Without Coexisting Diabetes. Journal of Clinical Hypertension, 2013, 15, 389-396.	1.0	7
179	Cost-Effectiveness of Osteoporosis Interventions for 'Incidental' Vertebral Fractures. American Journal of Medicine, 2013, 126, 169.e9-169.e17.	0.6	12
180	Health related quality of life measures in Arabic speaking populations: A systematic review on cross-cultural adaptation and measurement properties. Quality of Life Research, 2013, 22, 213-229.	1.5	58

#	Article	IF	CITATIONS
181	6-Month Follow Up Among Participants from the Healthy Eating and Active Living for Diabetes in Primary Care Networks Trial: A Qualitative Study. Canadian Journal of Diabetes, 2013, 37, S19.	0.4	1
182	Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. Lancet Diabetes and Endocrinology,the, 2013, 1, 132-139.	5.5	35
183	The Alberta Diabetes and Physical Activity Trial (ADAPT):A Randomized Trial Evaluating Theory-Based Interventions to Increase Physical Activity in Adults with Type 2 Diabetes. Annals of Behavioral Medicine, 2013, 45, 45-56.	1.7	43
184	Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax, 2013, 68, 658-663.	2.7	51
185	Detection Bias and Overestimation of Bladder Cancer Risk in Type 2 Diabetes: A matched cohort study. Diabetes Care, 2013, 36, 3070-3075.	4.3	26
186	Exenatide may improve maintenance of HbA1c targets, with less hypoglycaemia, but more early adverse effects when compared with low-dose glimepiride. Evidence-Based Medicine, 2013, 18, e42-e42.	0.6	1
187	Measuring Health Literacy in Individuals With Diabetes. Health Education and Behavior, 2013, 40, 42-55.	1.3	83
188	Adding Pharmacists to Primary Care Teams Increases Guideline-Concordant Antiplatelet Use in Patients with Type 2 Diabetes: Results from a Randomized Trial. Annals of Pharmacotherapy, 2013, 47, 43-48.	0.9	17
189	Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure. Circulation: Heart Failure, 2013, 6, 395-402.	1.6	282
190	Clinical and socioâ€demographic factors associated with diabetic ketoacidosis hospitalization in adults with Type 1 diabetes. Diabetic Medicine, 2013, 30, 567-573.	1.2	36
191	Evaluating the introduction of a computerized prior-authorization system on the completeness of drug exposure data. Pharmacoepidemiology and Drug Safety, 2013, 22, 551-555.	0.9	5
192	Risks of Gestational Diabetes and Preeclampsia Over the Last Decade in a Cohort of Alberta Women. Journal of Obstetrics and Gynaecology Canada, 2013, 35, 986-994.	0.3	40
193	A Systematic Review and Meta-Analysis to Assess Patient-Reported Outcomes after Lung Cancer Surgery. Scientific World Journal, The, 2013, 2013, 1-7.	0.8	26
194	Enrolment in primary care networks: impact on outcomes and processes of care for patients with diabetes. Cmaj, 2012, 184, E144-E152.	0.9	74
195	Interventions to Improve Influenza and Pneumococcal Vaccination Rates Among Community-Dwelling Adults: A Systematic Review and Meta-Analysis. Annals of Family Medicine, 2012, 10, 538-546.	0.9	117
196	Activation of Antioxidant Response Element in Mouse Primary Cortical Cultures with Sesquiterpene Lactones Isolated from Tanacetum parthenium. Planta Medica, 2012, 78, 1725-1730.	0.7	28
197	Utilization of General and Specialized Cardiac Care by People With Schizophrenia. Psychiatric Services, 2012, 63, 237-242.	1.1	13
198	Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. Cmaj, 2012, 184, E675-E683.	0.9	140

#	Article	IF	CITATIONS
199	Mortality After Incident Cancer in People With and Without Type 2 Diabetes. Diabetes Care, 2012, 35, 299-304.	4.3	381
200	Applying the RE-AIM framework to the Alberta's Caring for Diabetes Project: a protocol for a comprehensive evaluation of primary care quality improvement interventions. BMJ Open, 2012, 2, e002099.	0.8	20
201	Increasing rates of diabetes amongst status Aboriginal youth in Alberta, Canada. International Journal of Circumpolar Health, 2012, 71, 18501.	0.5	14
202	Population-level response shift: novel implications for research. Quality of Life Research, 2012, 21, 1495-1498.	1.5	6
203	Trajectories of health-related quality of life differ by age among adults: Results from an eight-year longitudinal study. Journal of Health Economics, 2012, 31, 207-218.	1.3	14
204	Balancing the risks and benefits for pioglitazone in type 2 diabetes. Diabetes Research and Clinical Practice, 2012, 98, 1-2.	1.1	4
205	Multimorbidity prevalence and patterns across socioeconomic determinants: a cross-sectional survey. BMC Public Health, 2012, 12, 201.	1.2	196
206	Healthy eating and active living for diabetes in primary care networks (HEALD-PCN): rationale, design, and evaluation of a pragmatic controlled trial for adults with type 2 diabetes. BMC Public Health, 2012, 12, 455.	1.2	17
207	Controlled trial of a collaborative primary care team model for patients with diabetes and depression: Rationale and design for a comprehensive evaluation. BMC Health Services Research, 2012, 12, 258.	0.9	34
208	Adding pharmacists to primary care teams reduces predicted longâ€ŧerm risk of cardiovascular events in Type 2 diabetic patients without established cardiovascular disease: results from a randomized trial. Diabetic Medicine, 2012, 29, 1433-1439.	1.2	32
209	Interventions to Increase Osteoporosis Treatment in Patients with †Incidentally' Detected Vertebral Fractures. American Journal of Medicine, 2012, 125, 929-936.	0.6	33
210	Thiazolidinedione use and cancer incidence in typeÂ2 diabetes: A systematic review and meta-analysis. Diabetes and Metabolism, 2012, 38, 475-484.	1.4	76
211	Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. Diabetes and Metabolism, 2012, 38, 485-506.	1.4	66
212	PP157. Risk of preeclampsia in pregnant women with gestational diabetes in Alberta. Pregnancy Hypertension, 2012, 2, 323-324.	0.6	2
213	Quantifying the Impact of Drug Exposure Misclassification due to Restrictive Drug Coverage in Administrative Databases: A Simulation Cohort Study. Value in Health, 2012, 15, 191-197.	0.1	17
214	Healthcare Costs for Initial Management of Children with New-Onset Type 1 Diabetes Mellitus in Central and Northern Alberta. Canadian Journal of Diabetes, 2012, 36, 128-132.	0.4	0
215	Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia, 2012, 55, 1607-1618.	2.9	191
216	Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia, 2012, 55, 1619-1632.	2.9	109

#	Article	IF	CITATIONS
217	The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes, Obesity and Metabolism, 2012, 14, 1-4.	2.2	47
218	Restrictive Drug Coverage Policies can Induce Substantial Drug Exposure Misclassification in Pharmacoepidemiologic Studies. Clinical Therapeutics, 2012, 34, 1379-1386.e3.	1.1	10
219	Validation of classification algorithms for childhood diabetes identified from administrative data. Pediatric Diabetes, 2012, 13, 229-234.	1.2	34
220	Predicting the Future Burden of Diabetes in Alberta from 2008 to 2035. Canadian Journal of Diabetes, 2011, 35, 274-281.	0.4	10
221	Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clinical Pharmacology and Therapeutics, 2011, 90, 625-629.	2.3	571
222	Levels of Evidence Needed for Changing Indications, Contraindications, and Food and Drug Administration Labeling: The Case of Metformin. Archives of Internal Medicine, 2011, 171, 1042.	4.3	4
223	Diabetes, cardiovascular disease, and health care use in people with and without schizophrenia. European Psychiatry, 2011, 26, 327-332.	0.1	17
224	Validation of diabetes case definitions using administrative claims data. Diabetic Medicine, 2011, 28, 424-427.	1.2	32
225	Determinants of quality of life in type 2 diabetes population: the inclusion of personality. Quality of Life Research, 2011, 20, 551-558.	1.5	24
226	Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia, 2011, 54, 25-31.	2.9	128
227	Meta-analysis of trial data may support a causal role of hyperglycaemia in cancer. Reply to Yang XL, Ma RCW, Chan JCN [letter]. Diabetologia, 2011, 54, 711-712.	2.9	1
228	Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia, 2011, 54, 2263-2271.	2.9	135
229	Nurse case-manager vs multifaceted intervention to improve quality of osteoporosis care after wrist fracture: randomized controlled pilot study. Osteoporosis International, 2011, 22, 223-230.	1.3	48
230	Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Osteoporosis International, 2011, 22, 1799-1808.	1.3	38
231	Determinants of quality of life in adults with type 1 and type 2 diabetes. Health and Quality of Life Outcomes, 2011, 9, 115.	1.0	84
232	Effect of Adding Pharmacists to Primary Care Teams on Blood Pressure Control in Patients With Type 2 Diabetes. Diabetes Care, 2011, 34, 20-26.	4.3	94
233	Analysis of drug coverage before and after the implementation of Canada's Common Drug Review. Cmaj, 2011, 183, E1259-E1266.	0.9	19
234	Recent epidemiologic trends of diabetes mellitus among status Aboriginal adults. Cmaj, 2011, 183, E803-E808.	0.9	44

#	Article	IF	CITATIONS
235	Risk of Breast Cancer After Onset of Type 2 Diabetes. Diabetes Care, 2011, 34, 2542-2544.	4.3	41
236	Changes in labelling for metformin use in patients with type 2 diabetes and heart failure: documented safety outweighs theoretical risks. Open Medicine, 2011, 5, e33-4.	1.5	3
237	Diabetes, Insulin Use, and Cancer Risk: Are Observational Studies Part of the Solution–or Part of the Problem?. Diabetes, 2010, 59, 1129-1131.	0.3	60
238	Using Instrument-Defined Health State Transitions to Estimate Minimally Important Differences for Four Preference-Based Health-Related Quality of Life Instruments. Medical Care, 2010, 48, 365-371.	1.1	150
239	Reflections on Self-Monitoring of Blood Glucose: Why Do We Recommend the Things We Do?. Canadian Pharmacists Journal, 2010, 143, 216-217.	0.4	0
240	Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia, 2010, 53, 1631-1637.	2.9	148
241	Glucose-lowering therapies and cancer risk: the trials and tribulations of trials and observations. Diabetologia, 2010, 53, 1823-1826.	2.9	9
242	Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia, 2010, 53, 2086-2088.	2.9	35
243	Assessing the use of health-related quality of life measures in the routine clinical care of lung-transplant patients. Quality of Life Research, 2010, 19, 371-379.	1.5	76
244	Alberta Diabetes and Physical Activity Trial (ADAPT): A randomized theory-based efficacy trial for adults with type 2 diabetes - rationale, design, recruitment, evaluation, and dissemination. Trials, 2010, 11, 4.	0.7	13
245	A Median Model for Predicting United States Population-Based EQ-5D Health State Preferences. Value in Health, 2010, 13, 278-288.	0.1	32
246	Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes, Obesity and Metabolism, 2010, 12, 47-53.	2.2	110
247	Association Between Direct Measures of Body Composition and Prognostic Factors in Chronic Heart Failure. Mayo Clinic Proceedings, 2010, 85, 609-617.	1.4	135
248	Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. Schizophrenia Research, 2010, 117, 75-82.	1.1	162
249	Comparison of Direct Body Composition Assessment Methods in Patients With Chronic Heart Failure. Journal of Cardiac Failure, 2010, 16, 867-872.	0.7	26
250	Physical activity levels and differences in the prevalence of diabetes between the United States and Canadaâ~†. Preventive Medicine, 2010, 50, 241-245.	1.6	18
251	Do researchers use pharmacists' communication as an outcome measure? A scoping review of pharmacist involvement in diabetes care. International Journal of Pharmacy Practice, 2010, 18, 183-193.	0.3	17
252	A comparison of drug coverage in alberta before and after the introduction of the national common drug review process. Healthcare Policy, 2010, 6, e117-44.	0.3	1

#	Article	IF	CITATIONS
253	Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches. Open Medicine, 2010, 4, e40-8.	1.5	3
254	Increasing Incidence and Prevalence of Diabetes among the Status Aboriginal Population in Urban and Rural Alberta, 1995–2006. Canadian Journal of Public Health, 2009, 100, 231-236.	1.1	18
255	The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease. Archives of Internal Medicine, 2009, 169, 1104.	4.3	88
256	Do the determinants of health differ between people living in the community and in institutions?. Social Science and Medicine, 2009, 69, 345-353.	1.8	22
257	The association of survey language (Spanish vs. English) with Health Utilities Index and EQ-5D index scores in a United States population sample. Quality of Life Research, 2009, 18, 1377-1385.	1.5	5
258	Lay media reporting of rosiglitazone risk: extent, messaging and quality of reporting. Cardiovascular Diabetology, 2009, 8, 40.	2.7	4
259	Metformin treatment in diabetes and heart failure: when academic equipoise meets clinical reality. Trials, 2009, 10, 12.	0.7	45
260	Hydrochlorothiazide and Atenolol Combination Antihypertensive Therapy: Effects of Drug Initiation Order. Clinical Pharmacology and Therapeutics, 2009, 86, 533-539.	2.3	22
261	Increasing incidence and prevalence with limited survival gains among rural Albertans with diabetes: a retrospective cohort study, 1995–2006. Diabetic Medicine, 2009, 26, 989-995.	1.2	20
262	Risk of Heart Failure in Patients With Recent-Onset Type 2 Diabetes: Population-Based Cohort Study. Journal of Cardiac Failure, 2009, 15, 152-157.	0.7	35
263	Survey of Pharmacist Activities and Attitudes in Diabetes Management. Canadian Pharmacists Journal, 2009, 142, 128-134.e2.	0.4	16
264	Relative Efficiency of the EQ-5D, HUI2, and HUI3 Index Scores in Measuring Health Burden of Chronic Medical Conditions in a Population Health Survey in the United States. Medical Care, 2009, 47, 53-60.	1.1	54
265	The Effect of Increasing Dialysis Dose in Overweight Hemodialysis Patients on Quality of Life: A 6-Week Randomized Crossover Trial. American Journal of Kidney Diseases, 2008, 51, 796-803.	2.1	11
266	Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the United Kingdom. Health and Quality of Life Outcomes, 2008, 6, 73.	1.0	60
267	Health Utilities Index Mark 3 showed valid in Alzheimer Disease, arthritis, and cataracts. Journal of Clinical Epidemiology, 2008, 61, 733-739.	2.4	24
268	Type of antidepressant therapy and risk of type 2 diabetes in people with depression. Diabetes Research and Clinical Practice, 2008, 79, 61-67.	1.1	75
269	The Darkening Cloud of Diabetes. Diabetes Care, 2008, 31, 2136-2142.	4.3	10
270	Multifaceted intervention to improve diagnosis and treatment of osteoporosis in patients with recent wrist fracture: a randomized controlled trial. Cmaj, 2008, 178, 569-575.	0.9	132

#	Article	IF	CITATIONS
271	The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. European Journal of Heart Failure, 2008, 10, 703-708.	2.9	90
272	Sex and Gender Discrepancies in Health-Related Quality of Life Outcomes Among Patients With Established Coronary Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2008, 1, 123-130.	0.9	77
273	Health-related Behaviours in Adults with Diabetes. Canadian Journal of Public Health, 2008, 99, 226-231.	1.1	18
274	Development of clinical indicators for type 2 diabetes. Canadian Pharmacists Journal, 2008, 141, 120-128.	0.4	6
275	Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis. Open Medicine, 2008, 2, e26-38.	1.5	1
276	The effect of specialist care within the first year on subsequent outcomes in 24 232 adults with new-onset diabetes mellitus: population-based cohort study. Quality and Safety in Health Care, 2007, 16, 6-11.	2.5	55
277	How Evidence-Based Are the Recommendations in Evidence-Based Guidelines?. PLoS Medicine, 2007, 4, e250.	3.9	199
278	Short-Term Risk for Stroke Is Doubled in Persons With Newly Treated Type 2 Diabetes Compared With Persons Without Diabetes. Stroke, 2007, 38, 1739-1743.	1.0	69
279	Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ: British Medical Journal, 2007, 335, 497.	2.4	293
280	Prospective Study of Hyperglycemia and Cancer Risk: Response to Stattin et al Diabetes Care, 2007, 30, e77-e77.	4.3	5
281	Quality of Life After Islet Transplant: Impact of the Number of Islet Infusions and Metabolic Outcome. Transplantation, 2007, 84, 664-666.	0.5	50
282	Use of the U.S. and U.K. Scoring Algorithm for the EuroQol-5D in an Economic Evaluation of Cardiac Care. Medical Care, 2007, 45, 269-273.	1.1	7
283	Atenolol as initial antihypertensive therapy: an observational study comparing first-line agents. Journal of Hypertension, 2007, 25, 1499-1505.	0.3	29
284	Health Care Costs and Mortality for Canadian Urban and Rural Patients with Diabetes: Population-Based Trends from 1993–2001. Clinical Therapeutics, 2007, 29, 1316-1324.	1.1	27
285	Do radiographic indices of distal radius fracture reduction predict outcomes in older adults receiving conservative treatment?. Clinical Radiology, 2007, 62, 65-72.	0.5	117
286	Racial/ethnic differences in preferences for the EQ-5D health states: results from the U.S. valuation study. Journal of Clinical Epidemiology, 2007, 60, 479-490.	2.4	43
287	Physical activity level and health-related quality of life in the general adult population: A systematic review. Preventive Medicine, 2007, 45, 401-415.	1.6	800
288	Prescription Drug Data and the National Diabetes Surveillance System Case Definition. Canadian Journal of Diabetes, 2007, 31, 47-53.	0.4	6

#	Article	IF	CITATIONS
289	A Comparison of EQ-5D Index Scores Derived from the US and UK Population-Based Scoring Functions. Medical Decision Making, 2007, 27, 321-326.	1.2	57
290	IHE Consensus Conference on Self-Monitoring in Diabetes: An Innovative Approach to Health Policy Development. Canadian Journal of Diabetes, 2007, 31, 18-19.	0.4	0
291	Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. British Journal of Dermatology, 2007, 156, 667-673.	1.4	119
292	Health care utilization and costs in Saskatchewan's registered Indian population with diabetes. BMC Health Services Research, 2007, 7, 126.	0.9	22
293	Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial. Osteoporosis International, 2007, 18, 261-270.	1.3	84
294	The usefulness of the EQ-5D in differentiating among persons with major depressive episode and anxiety. Quality of Life Research, 2007, 16, 749-754.	1.5	38
295	Evaluating pharmacists' experience using diabetes practice tools: A pilot study. Canadian Pharmacists Journal, 2007, 140, 312-319.	0.4	1
296	Medication Nonadherence and Subsequent Risk of Hospitalisation and Mortality among Older Adults. Drugs and Aging, 2006, 23, 345-356.	1.3	75
297	Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin. Diabetes Care, 2006, 29, 254-258.	4.3	845
298	Misinterpretation with norm-based scoring of health status in adults with type 1 diabetes. Health and Quality of Life Outcomes, 2006, 4, 15.	1.0	10
299	A cross-sectional study of health-related quality of life deficits in individuals with comorbid diabetes and cancer. Health and Quality of Life Outcomes, 2006, 4, 17.	1.0	39
300	Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health and Quality of Life Outcomes, 2006, 4, 89.	1.0	98
301	Health Care Use and Costs in the Decade After Identification of Type 1 and Type 2 Diabetes: A population-based study. Diabetes Care, 2006, 29, 2403-2408.	4.3	50
302	Health Utilities Index mark 3 demonstrated construct validity in a population-based sample with type 2 diabetes. Journal of Clinical Epidemiology, 2006, 59, 472-477.	2.4	31
303	Educational intervention to reduce falls and fear of falling in patients after fragility fracture: Results of a controlled pilot study. Preventive Medicine, 2006, 42, 316-319.	1.6	40
304	Understanding the Determinants of Health for People With Type 2 Diabetes. American Journal of Public Health, 2006, 96, 1649-1655.	1.5	96
305	Self-monitoring in Type 2 diabetes: a randomized trial of reimbursement policy. Diabetic Medicine, 2006, 23, 1247-1251.	1.2	27
306	Cross-sectional validity of a modified Edmonton symptom assessment system in dialysis patients: A simple assessment of symptom burden. Kidney International, 2006, 69, 1621-1625.	2.6	211

#	Article	IF	CITATIONS
307	Comment on: Evans JM, Ogston SA, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936. Diabetologia, 2006, 49, 2805-2806.	2.9	4
308	Utilization of diabetes medication and cost of testing supplies in Saskatchewan, 2001. BMC Health Services Research, 2006, 6, 159.	0.9	17
309	Longitudinal validation of a modified Edmonton symptom assessment system (ESAS) in haemodialysis patients. Nephrology Dialysis Transplantation, 2006, 21, 3189-3195.	0.4	155
310	Evidence and advocacy: Are all things considered?. Cmaj, 2006, 174, 1856-1856.	0.9	7
311	Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. Cmaj, 2006, 174, 169-174.	0.9	186
312	Diabetes, Fitness, and Body Mass Index. Archives of Internal Medicine, 2006, 166, 1326.	4.3	1
313	Improving Blood Pressure Management in Patients with Diabetes: The Design of the SCRIP-HTN Study. Canadian Pharmacists Journal, 2006, 139, 1-4.	0.4	5
314	Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin: Response to Farooki and Schneider. Diabetes Care, 2006, 29, 1990-1991.	4.3	118
315	The Natural History of LDL Control in Type 2 Diabetes: A prospective study of adherence to lipid guidelines. Diabetes Care, 2006, 29, 2506-2508.	4.3	4
316	Type 2 diabetes does not increase risk of depression. Cmaj, 2006, 175, 42-46.	0.9	68
317	History of Depression Increases Risk of Type 2 Diabetes in Younger Adults. Diabetes Care, 2005, 28, 1063-1067.	4.3	109
318	Self-Reported Health Status of the General Adult U.S. Population as Assessed by the EQ-5D and Health Utilities Index. Medical Care, 2005, 43, 1078-1086.	1.1	343
319	US Valuation of the EQ-5D Health States. Medical Care, 2005, 43, 203-220.	1.1	1,145
320	Valuations of EQ-5D Health States. Medical Care, 2005, 43, 221-228.	1.1	202
321	Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabetic Medicine, 2005, 22, 497-502.	1.2	142
322	Secondary Failure Rates Associated with Metformin and Sulfonylurea Therapy for Type 2 Diabetes Mellitus. Pharmacotherapy, 2005, 25, 810-816.	1.2	42
323	Long-Term Impact of a Community Pharmacist Intervention on Cholesterol Levels in Patients at High Risk for Cardiovascular Events: Extended Follow-up of the Second Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP-plus). Pharmacotherapy, 2005, 25, 110-115.	1.2	28
324	Responsiveness of generic health-related quality of life measures in stroke. Quality of Life Research, 2005, 14, 207-219.	1.5	139

#	Article	IF	CITATIONS
325	Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Quality of Life Research, 2005, 14, 1311-1320.	1.5	167
326	Understanding the complex associations between patient–provider relationships, self-care behaviours, and health-related quality of life in type 2 diabetes: A structural equation modeling approach. Quality of Life Research, 2005, 14, 1489-1500.	1.5	70
327	Relationship between number, timing, and type of pharmacist interventions and patient outcomes. American Journal of Health-System Pharmacy, 2005, 62, 1798-1801.	0.5	8
328	Physician Perceptions of Enhanced Community Pharmacist Care in Cholesterol Management. Canadian Pharmacists Journal, 2005, 138, 33-39.	0.4	4
329	Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure. Diabetes Care, 2005, 28, 2345-2351.	4.3	363
330	A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes. Diabetes Care, 2005, 28, 736-744.	4.3	150
331	Generalizability and Persistence of a Multifaceted Intervention for Improving Quality of Care for Rural Patients With Type 2 Diabetes. Diabetes Care, 2005, 28, 783-788.	4.3	19
332	The Effectiveness of Â-Blockers After Myocardial Infarction in Patients With Type 2 Diabetes. Diabetes Care, 2005, 28, 2113-2117.	4.3	11
333	A cohort study found the RAND-12 and Health Utilities Index Mark 3 demonstrated construct validity in high-risk primary care patients. Journal of Clinical Epidemiology, 2005, 58, 138-141.	2.4	40
334	A Controlled Trial To Increase Detection and Treatment of Osteoporosis in Older Patients with a Wrist Fracture. Annals of Internal Medicine, 2004, 141, 366.	2.0	148
335	Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis. Cmaj, 2004, 171, 1189-1192.	0.9	135
336	Lack of insurance coverage for testing supplies is associated with poorer glycemic control in patients with type 2 diabetes. Cmaj, 2004, 171, 39-43.	0.9	34
337	Reduced Fear of Hypoglycemia in Successful Islet Transplantation. Diabetes Care, 2004, 27, 624-625.	4.3	46
338	Reduced Mortality Associated With the Use of ACE Inhibitors in Patients With Type 2 Diabetes. Diabetes Care, 2004, 27, 1330-1334.	4.3	58
339	Agreement Between Patient and Proxy Assessments of Health-Related Quality of Life After Stroke Using the EQ-5D and Health Utilities Index. Stroke, 2004, 35, 607-612.	1.0	165
340	Improvements in Patient-Reported Outcomes Associated With an Intervention to Enhance Quality of Care for Rural Patients With Type 2 Diabetes: Results of a controlled trial. Diabetes Care, 2004, 27, 1306-1312.	4.3	46
341	Statin use in Type 2 diabetes mellitus is associated with a delay in starting insulin. Diabetic Medicine, 2004, 21, 962-967.	1.2	26
342	Greater Effect of Enhanced Pharmacist Care on Cholesterol Management in Patients with Diabetes Mellitus: A Planned Subgroup Analysis of the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Pharmacotherapy, 2004, 24, 389-394.	1.2	26

#	Article	IF	CITATIONS
343	Performance of the RAND-12 and SF-12 summary scores in type 2 diabetes. Quality of Life Research, 2004, 13, 449-456.	1.5	55
344	Construct validity of the RAND-12 and Health Utilities Index Mark 2 and 3 in type 2 diabetes. Quality of Life Research, 2004, 13, 435-448.	1.5	44
345	Primary health care teams: team members' perceptions of the collaborative process. Journal of Interprofessional Care, 2004, 18, 75-78.	0.8	74
346	A multicenter disease management program for hospitalized patients with heart failure. Journal of Cardiac Failure, 2004, 10, 473-480.	0.7	127
347	Radiologic and patient-reported functional outcomes in an elderly cohort with conservatively treated distal radius fractures. Journal of Hand Surgery, 2004, 29, 1121-1127.	0.7	170
348	Letter to the editor. American Heart Journal, 2004, 148, e3.	1.2	0
349	Effect of community pharmacist intervention on cholesterol levels in patients at high risk of cardiovascular events: the second study of cardiovascular risk intervention by pharmacists (SCRIP-plus). American Journal of Medicine, 2004, 116, 130-133.	0.6	50
350	Underuse of aspirin in type 2 diabetes mellitus: Prevalence and correlates of therapy in rural Canada. Clinical Therapeutics, 2004, 26, 439-446.	1.1	23
351	Treatment gaps for hypertension management in rural Canadian patients with type 2 diabetes mellitus*1. Clinical Therapeutics, 2004, 26, 598-606.	1.1	29
352	Shifting from Inpatient to Outpatient Treatment of Deep Vein Thrombosis in a Tertiary Care Center: A Cost-Minimization Analysis. Pharmacotherapy, 2003, 23, 301-309.	1.2	15
353	Compliance with Clinical Practice Guidelines for Type 2 Diabetes in Rural Patients: Treatment Gaps and Opportunities for Improvement. Pharmacotherapy, 2003, 23, 659-665.	1.2	64
354	Health-related quality of life deficits associated with varying degrees of disease severity in type 2 diabetes. Health and Quality of Life Outcomes, 2003, 1, 78.	1.0	35
355	Controlled Trial of a Multifaceted Intervention for Improving Quality of Care for Rural Patients With Type 2 Diabetes. Diabetes Care, 2003, 26, 3061-3066.	4.3	85
356	A Comparison of the Health Utilities Indices Mark 2 and Mark 3 in Type 2 Diabetes. Medical Decision Making, 2003, 23, 489-501.	1.2	33
357	The cost of major comorbidity in people with diabetes mellitus. Cmaj, 2003, 168, 1661-7.	0.9	36
358	A Randomized Trial of the Effect of Community Pharmacist Intervention on Cholesterol Risk Management <subtitle>The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP)</subtitle> . Archives of Internal Medicine, 2002, 162, 1149.	4.3	251
359	Decreased Mortality Associated With the Use of Metformin Compared With Sulfonylurea Monotherapy in Type 2 Diabetes. Diabetes Care, 2002, 25, 2244-2248.	4.3	403
360	Dialysis Adequacy and Health Related Quality of Life in Hemodialysis Patients. ASAIO Journal, 2002, 48, 565-569.	0.9	55

#	Article	IF	CITATIONS
361	Underutilisation of ACE Inhibitors in Patients with Congestive Heart Failure. Drugs, 2001, 61, 2021-2033.	4.9	61
362	Economic Impact of Community Pharmacist Intervention in Cholesterol Risk Management: An Evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists. Pharmacotherapy, 2001, 21, 627-635.	1.2	42
363	Practice-Based Research: Lessons from Community Pharmacist Participants. Pharmacotherapy, 2001, 21, 731-739.	1.2	50
364	Productivity Losses Associated With Diabetes in the U.S Diabetes Care, 2001, 24, 257-261.	4.3	106
365	Pharmacists' Attitudes Toward Diabetes. Journal of the American Pharmacists Association, 2000, 40, 371-377.	0.6	20
366	Health-Related Quality of Life for Adults with Cystic Fibrosis: A Regression Approach to Assessing the Impact of Recombinant Human DNase. Pharmacotherapy, 2000, 20, 1167-1174.	1.2	21
367	Gender Differences in Labetalol Kinetics: Importance of Determining Stereoisomer Kinetics for Racemic Drugs. Pharmacotherapy, 2000, 20, 622-628.	1.2	26
368	Using Focus Groups to Identify Barriers to Drug Use in Patients with Congestive Heart Failure. Pharmacotherapy, 2000, 20, 823-829.	1.2	37
369	Comparison of Finnish and U.Sbased Visual Analog Scale Valuations of the EQ-5D Measure. Medical Decision Making, 2000, 20, 281-289.	1.2	39
370	Comparison of the EQ-5D and SF-12 Health Surveys in a General Population Survey in Alberta, Canada. Medical Care, 2000, 38, 115-121.	1.1	240
371	Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. International Journal of Clinical Pharmacology and Therapeutics, 2000, 38, 53-60.	0.3	101
372	CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. Journal of Pharmacology and Experimental Therapeutics, 2000, 294, 1099-105.	1.3	43
373	Cost of Care for Individuals with Cystic Fibrosis: A Regression Approach to Determining the Impact of Recombinant Human DNase. Pharmacotherapy, 1999, 19, 1159-1166.	1.2	30
374	Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): A Randomized Trial Design of the Effect of a Community Pharmacist Intervention Program on Serum Cholesterol Risk. Annals of Pharmacotherapy, 1999, 33, 910-919.	0.9	50
375	Replicability of SF-36 Summary Scores by the SF-12 in Stroke Patients. Stroke, 1999, 30, 1213-1217.	1.0	107
376	The Impact of Pharmacist Interventions on Health-Related Quality of Life. Annals of Pharmacotherapy, 1999, 33, 1167-1172.	0.9	38
377	Comparison of the EQ-5D and SF-12 in an adult US sample. , 1998, 7, 155-166.		262
378	Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample. Pharmacoeconomics, 1998, 13, 421-433.	1.7	225

#	Article	IF	CITATIONS
379	Reassessing the Relevance of Pharmacoeconomic Analyses in Formulary Decisions. Pharmacoeconomics, 1998, 13, 479-485.	1.7	17
380	The Structure of Satisfaction with Pharmacy Services. Medical Care, 1998, 36, 244-250.	1.1	33
381	Construct Validities of the Quality of Well-Being Scale and the MOS-HIV-34 Health Survey for HIV-infected Patients. Medical Decision Making, 1997, 17, 439-446.	1.2	26
382	Drug-related morbidity and mortality and the economic impact of pharmaceutical care. American Journal of Health-System Pharmacy, 1997, 54, 554-558.	0.5	129
383	Influence of Race or Ethnicity on Pharmacokinetics of Drugs. Journal of Pharmaceutical Sciences, 1997, 86, 1328-1333.	1.6	117
384	Self-Efficacy Theory as a Framework for Community Pharmacy-Based Diabetes Education Programs. The Diabetes Educator, 1996, 22, 237-241.	2.6	41
385	Health-Related Quality of Life of Diabetic Pima Indians. Medical Care, 1996, 34, 97-102.	1.1	63
386	Humanistic Outcomes. , 1996, , 403-445.		2
387	Racial Differences in β-Adrenoceptor-Mediated Responsiveness. Journal of Cardiovascular Pharmacology, 1995, 25, 90-96.	0.8	52
388	Evaluation of Published Pharmacoeconomic Studies. Journal of Pharmacy Practice, 1995, 8, 156-166.	0.5	2
389	Metoprolol minimizes nighttime blood pressure dip in hypertensive black males. American Journal of Hypertension, 1995, 8, 254-259.	1.0	9
390	Influence of metabolites on protein binding of verapamil enantiomers British Journal of Clinical Pharmacology, 1995, 39, 536-538.	1.1	6
391	Drug-Related Morbidity and Mortality. Archives of Internal Medicine, 1995, 155, 1949.	4.3	577
392	Effect of Pravastatin on Outcomes after Cardiac Transplantation. New England Journal of Medicine, 1995, 333, 621-627.	13.9	1,215
393	Drug-related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine, 1995, 155, 1949-56.	4.3	182
394	Pharmacoeconomic analysis in formulary decisions: An international perspective. American Journal of Health-System Pharmacy, 1994, 51, 2593-2598.	0.5	8
395	Pharmacoeconomic analysis in formulary decisions: an international perspective. American Journal of Hospital Pharmacy, 1994, 51, 2593-8.	0.2	8
396	Predictors of medication noncompliance in a sample of older adults. Clinical Therapeutics, 1994, 16, 110-7.	1.1	87

#	Article	IF	CITATIONS
397	Racial differences in lymphocyte beta-receptor sensitivity to propranolol. Life Sciences, 1993, 53, 297-304.	2.0	13
398	Racial differences in propranolol pharmacokinetics. Clinical Pharmacology and Therapeutics, 1992, 51, 495-500.	2.3	33
399	Health-related quality of life and its determinants in paediatric arterial ischaemic stroke survivors. , 0, .		1
400	Anti-Hyperglycemic Medication Adherence and Health Services Utilization in People with Diabetes: A Longitudinal Study of Alberta's Tomorrow Project. Patient Preference and Adherence, 0, Volume 16, 1457-1467.	0.8	2